{
    "id": 221,
    "entrez_name": "TP53",
    "entrez_id": 7157,
    "name": "DELETERIOUS MUTATION",
    "description": "Deleterious mutations are mutations of TP53 with prior characterization demonstrating significant deleterious effect on TP53 protein function.\nInactivating TP53 mutations prevent on target activity and efficacy of MDM2-TP53 interaction inhibitors.",
    "gene_id": 45,
    "type": "variant",
    "variant_types": [],
    "civic_actionability_score": 78,
    "coordinates": {
        "chromosome": "17",
        "start": 7571720,
        "stop": 7590856,
        "reference_bases": null,
        "variant_bases": null,
        "representative_transcript": "ENST00000269305.4",
        "chromosome2": null,
        "start2": null,
        "stop2": null,
        "representative_transcript2": null,
        "ensembl_version": 75,
        "reference_build": "GRCh37"
    },
    "evidence_items": {
        "id": 2967,
        "name": "EID2967",
        "description": "MDM2 Inhibitor screen in a panel of 260 cancer cell lines with well characterized TP53 status shows that only cancer cell lines with unaltered TP53 may be sensitive to MDM2 Inhibitor AMGMDS3, while those with p53 mutations demonstrated resistance.",
        "disease": {
            "id": 216,
            "name": "Cancer",
            "display_name": "Cancer",
            "doid": "162",
            "url": "http://www.disease-ontology.org/?id=DOID:162"
        },
        "drugs": [
            {
                "id": 490,
                "name": "AMGMDS3",
                "ncit_id": null,
                "aliases": []
            }
        ],
        "rating": 4,
        "evidence_level": "D",
        "evidence_type": "Predictive",
        "clinical_significance": "Resistance",
        "evidence_direction": "Supports",
        "variant_origin": "Somatic",
        "drug_interaction_type": null,
        "status": "accepted",
        "type": "evidence",
        "source": {
            "id": 1696,
            "name": "Identifying the determinants of response to MDM2 inhibition.",
            "citation": "Saiki et al., 2015, Oncotarget",
            "citation_id": "25730903",
            "source_type": "PubMed",
            "asco_abstract_id": null,
            "source_url": "http://www.ncbi.nlm.nih.gov/pubmed/25730903",
            "open_access": true,
            "pmc_id": "PMC4480710",
            "publication_date": {
                "year": 2015,
                "month": 4,
                "day": 10
            },
            "journal": "Oncotarget",
            "full_journal_title": "Oncotarget",
            "status": "fully curated",
            "is_review": false,
            "clinical_trials": []
        },
        "variant_id": 221,
        "phenotypes": []
    },
    "variant_groups": [],
    "assertions": [],
    "variant_aliases": [],
    "hgvs_expressions": [],
    "clinvar_entries": [],
    "allele_registry_id": null
}